Literature DB >> 31182347

Executive summary of the SEORL CCC-SEEN consensus statement on post-thyroidectomy hypoparathyroidism.

Alejandro Castro1, Amelia Oleaga2, Pablo Parente Arias3, Miguel Paja2, Elisa Gil Carcedo4, Cristina Álvarez Escolá5.   

Abstract

Hypoparathyroidism is the most common complication after total or completion thyroidectomy. It is defined as the presence of hypocalcemia accompanied by low or inappropriately normal parathyroid hormone (PTH) levels. Acute hypocalcemia is a potential lethal complication. Hypocalcemia treatment is based on endovenous or oral calcium supplements as well as oral calcitriol, depending on the severity of the symptoms. The risk of clinical hypocalcemia after bilateral thyroidectomy is considered very low if postoperative intact PTH decrease less than 80% with respect to preoperative levels. These patients could be discharged home without treatment, although this threshold may vary between institutions, and we recommend close surveillance in cases with increased risk (Graves disease, large goiters, reinterventions or evidence of parathyroid gland removal). Long-term treatment objectives are to control the symptoms and to keep serum calcium levels at the lower limit of the normal range, while preserving the calcium phosphate product and avoiding hypercalciuria.
Copyright © 2019 SEEN y SED. Publicado por Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Hipocalcemia; Hipoparatiroidismo; Hormona paratiroidea; Hypocalcemia; Hypoparathyroidism; Parathyroid hormone; Thyroidectomy; Tiroidectomía

Mesh:

Substances:

Year:  2019        PMID: 31182347     DOI: 10.1016/j.endinu.2019.03.015

Source DB:  PubMed          Journal:  Endocrinol Diabetes Nutr (Engl Ed)        ISSN: 2530-0180            Impact factor:   1.417


  1 in total

1.  Practice patterns for chronic hypoparathyroidism: data from patients and physicians in France.

Authors:  Jean-Philippe Bertocchio; Natalie Grosset; Lionel Groussin; Peter Kamenický; Fabrice Larceneux; Anne Lienhardt-Roussie; Agnès Linglart; Gérard Maruani; Eric Mirallie; François Pattou; Riyad N H Seervai; Coralie Sido; Caroline Silve; Aurélie Vilfaillot; Antoine Tabarin; Marie-Christine Vantyghem; Pascal Houillier
Journal:  Endocr Connect       Date:  2022-01-31       Impact factor: 3.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.